Explore Immuno 2024: Unlocking Future Insights in Immuno Research
Join 400+ leaders, experts, and researchers at Immuno 2024, connecting pharmaceutical and biotech representatives as well as academia for high-level discussions on the latest innovations in immune-oncology discovery and therapeutics development.
Featuring our ever-popular 9th Annual Advances in Immuno-Oncology Congress and the 2nd Annual Targets & Cell Types Congress, Immuno 2024 is attended by over 400 senior level attendees in London to network, debate, and discuss the industry’s most pressing challenges and opportunities, fostering partnerships and collaborations in the field.
Do not miss out on attending these events to stay at the forefront of the latest advancements pushing the immune-oncology industry forward – from the discovery and development of cell and gene, antibody, and combination therapies, through to the utilisation of omics techniques and technologies in IO as well as novel target identification and validation strategies. New to the agenda is the introduction of the Innovation & Collaboration track showcasing emerging biotechs and pioneering academic spin offs entering the market.
Join 400+ leaders, experts, and researchers at Immuno 2024, connecting pharmaceutical and biotech representatives as well as academia for high-level discussions on the latest innovations in immune-oncology discovery and therapeutics development.
Featuring our ever-popular 9th Annual Advances in Immuno-Oncology Congress and the 2nd Annual Targets & Cell Types Congress, Immuno 2024 is attended by over 400 senior level attendees in London to network, debate, and discuss the industry’s most pressing challenges and opportunities, fostering partnerships and collaborations in the field.
Do not miss out on attending these events to stay at the forefront of the latest advancements pushing the immune-oncology industry forward – from the discovery and development of cell and gene, antibody, and combination therapies, through to the utilisation of omics techniques and technologies in IO as well as novel target identification and validation strategies. New to the agenda is the introduction of the Innovation & Collaboration track showcasing emerging biotechs and pioneering academic spin offs entering the market.
